CRTX · Cortexyme Inc

-

Please sign in to comment on CRTX

1 Comment

Admin

4 years ago

Cortexyme, Inc is currently in a long term uptrend where the price is trading 44.5% above its 200 day moving average.

From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.

Cortexyme, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.

Its net income has dropped by 66.0% to $-21M since the same quarter in the previous year.

Finally, its free cash flow fell by 21.2% to $-13M since the same quarter in the previous year.

Based on the above factors, Cortexyme, Inc gets an overall score of 2/5.

Sector	Healthcare
ISIN	US22053A1079
Industry	Biotechnology
Exchange	NASDAQ
CurrencyCode	USD

Market Cap	70M
Target Price	22.25
PE Ratio	None
Beta	1.4
Dividend Yield	0.0%

ABOUT

Cortexyme Inc

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

CRTX · Cortexyme Inc

-

Cortexyme Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Cortexyme Inc using a moving average strategy